Asahi Kasei Bioprocess and Axolabs partner to accelerate oligonucleotide therapeutics development
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
Contributing to lower risk of potentially carcinogenic nitrosamine impurities in pharmaceuticals
The bioprocess business will continue to pioneer contributions to safety and productivity in the manufacture of biotherapeutics
The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg
With the new facility, the company underlines its commitment to meet the substantially growing demand for its MCC
Bionova Scientific’s process development capabilities are particularly highly regarded in the industry, and it has a rich track record regarding complex next-generation antibody drugs, which are typically challenging to manufacture
The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
Subscribe To Our Newsletter & Stay Updated